Dyne Therapeutics' (DYN) recent Duchenne muscular dystrophy, or DMD, study data further validates the company's Force platform, Dyne's drug delivery technology, Morgan Stanley said in a Tuesday note.

On Monday, Dyne Therapeutics said its phase 1/2 trial of zeleciment rostudirsen in an expanded group of Duchenne muscular dystrophy patients met its primary endpoint.

"The positive results for z-rostudirsen increase the potential for accelerated approval in DMD and enhance its competitive profile," the Morgan Stanley analysts said.

Morgan Stanley further increased its probability for success in DMD to 70% from 55% previously and peak market share in US to 42% from 25%, and in EU to 25% from 20%.

The firm raised price target on Dyne Therapeutics to $50 from $46, along with an overweight rating.

Price: 19.24, Change: -2.96, Percent Change: -13.32